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Abstract
Background: It has been reported that triple negative phenotype is characterized by aggressive clinical history
in Western breast cancer patients, however its pattern of metastatic spread had never been reported in the
Chinese population. Considering racial disparities, we sought to analyze the spread pattern for different sites of
first recurrence in Chinese triple negative breast cancers.
Methods: A retrospective study of 1662 patients was carried out from a large database of breast cancer patients
undergoing surgery between January 1, 2000 and March 31, 2004 at the Cancer Hospital, Fudan University,
Shanghai, China. Survival curves were generated using the Kaplan-Meier method and annual relapse hazards were
estimated by the hazard function.
Results: We found a statistically significant difference in relapse-free survival (RFS) for locoregional and visceral
recurrence (P = 0.007 and P = 0.025, respectively) among the triple negative, ERBB2+ and HR+/ERBB2- subgroups
in univariate analysis. In the multivariate Cox proportional hazards regression analysis, RFS for either locoregional
or visceral relapse in the triple negative category was inferior to that in HR+/ERBB2- patients (P = 0.027 and P =
0.005, respectively), but comparable to that in ERBB2+ women (both P >0.05). Furthermore, the early relapse
peak appeared later in the triple negative group than that in the ERBB2+ counterpart for both locoregional and
visceral relapse. On the other hand, when compared with triple negative breast cancers, a significantly lower risk
of developing bone relapse was discerned for ERBB2+ women (P = 0.048; HR = 0.384, 95% CI 0.148-0.991), with
the borderline significance for HR+/ERBB2- breast cancers (P = 0.058; HR = 0.479, 95% CI 0.224-1.025). In terms
of bone metastasis, the hazard rate remained higher for the triple negative category than that for the ERBB2+
subtype.
Conclusion: Based on the site-specific spread pattern in different subgroups, the triple negative category of
breast cancers in the Chinese population exhibits a different pattern of relapse, which indicates that different
organotropism may be due to the different intrinsic subtypes. A better knowledge of the triple negative category
is warranted for efficacious systemic regimens to decrease and/or delay the relapse hazard.
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Recent advances in genomic techniques have led to the
classification of breast cancer into five distinct subtypes:
the luminal A, luminal B, ERBB2+, normal breast-like and
basal-like subtype [1]. The fifth group is roughly synony-
mous with triple negative breast cancer, featuring absent
expression of estrogen, progesterone and ERBB2 recep-
tors. Although systemic therapy, together with targeted
treatment, has revealed a considerable impact on the
improvement of prognosis, there is to date no recom-
mended regimen for triple negative women due to the
scarcity of data as well as the dearth of target.
The triple negative category generally makes up 10-15% of
breast cancers [2]. However, the prevalence varies widely
by race. This subgroup occurred at a higher incidence
(39%) in pre-menopausal African American women [3],
whereas there was a rather lower frequency (18%) in Chi-
nese patients [4], much similar to the Japanese series (8-
14%) [5,6]. Manifold data demonstrated the detrimental
effect of triple negative phenotype on survival in Western
populations [3,7-13], as opposed to more favorable prog-
nosis in Chinese as well as Japanese counterparts [4,5].
Despite racial preference, these results provide support for
the increasing recognition that breast cancer is a heteroge-
neous disease categorized as different subgroups with a
wide spectrum of clinical, pathological and molecular fea-
tures [8]. Therefore, it hints at a demand for further inves-
tigation on the intrinsic characteristics of triple negative
tumors in different populations including Chinese
patients.
Nowadays, there is an increasing interest in hazard func-
tion, which highlights changes of the event probability
over time. When it comes to the triple negative category,
its unique time distribution of recurrence risk, as distin-
guished from that for the other subtypes, has been
reported in both Western series and our previous study
[4,10]. Nevertheless, such information is still not availa-
ble with regard to different sites of first recurrence. Cur-
rent data indicate that the triple negative group is more
prone to visceral metastases, local relapse and cerebral
metastases rather than bone metastases as compared to
women with non-triple negative tumors [13-15]. Unfortu-
nately, prior studies were almost confined to Western
populations and almost conducted by way of dichotomi-
zation. And most dichotomized cases according to hor-
mone receptor status or as triple negative/non-triple
negative, which obscures the superiority of ERBB2 status
to hormone receptor (HR) status as a prognosticator in
breast cancer [16]. Considering the discrepancies in races
and subgroups, it remains unclear whether the site-spe-
cific relapse pattern is similar or not for Chinese triple
negative patients, which serves as a reminder of the need
for exploration to promote a better understanding of orga-
notropic nature between various races and subgroups.
In view of the above points, a retrospective analysis was
carried out to further elucidate the spread pattern for dif-
ferent sites of first recurrence in Chinese triple negative
breast cancer patients as compared to ERBB2+ and HR+/
ERBB2- peers. In this way, we sought to get a clear picture
of the predisposition to organ metastases for Chinese tri-
ple negative breast cancer patients, thereby, shedding
more light on the underlying distinction in biological
behavior between different subgroups.
Methods
Patients
A total of 1662 patients were selected retrospectively from
a large database of patients who underwent surgery
between January 1, 2000 and March 31, 2004 at the Can-
cer Hospital, Fudan University, Shanghai, China.
Before surgery, the following evaluations were mandatory
for each patient as complete physical examination, chest
radioscopy, bilateral mammography, ECG, ultrasonogra-
phy of breasts, axillary fossa, cervical parts, abdomen, and
pelvis, complete blood count, and routine biochemical
tests to make an exact staging. Thereafter, each patient
received lumpectomy or mastectomy followed by adju-
vant therapy according to the guidelines or recommenda-
tions used at the time of surgery.
Eligibility criteria for this analysis, similar to other rele-
vant reports [17,18], included female gender, an initial
diagnosis of unilateral primary breast cancer without dis-
tant metastases, at least 2 months of follow-up informa-
tion for disease recurrence, and complete data on the
following: age, tumor size, number of involved axillary
lymph nodes, status of estrogen receptor (ER), progester-
one receptor (PR) as well as ERBB2. All eligible patients in
the database were included. All data were entered into a
computerized database and verified to minimize errors in
data entry.
Follow-up information regarding tumor recurrence and
survival status was accomplished through patients' clinic
visits with records kept in the computerized database of
the outpatient department, personal contact with the
patient as well as the assistance of Shanghai Center for
Disease Control and Prevention (CDC). Thereinto, per-
sonal contact with the patient referred to routine corre-
spondence or telephone visits, which were carried out at
the Cancer Hospital, Fudan University every 3 months
during the first two years, every 6 months during the next
two years and once a year thereafter. As this was a retro-
spective study without any medical intervention, the ethi-
cal approval was not required.
Immunohistochemistry
Immunohistochemical staining was carried out as a stand-
ard operating procedure in the pathology department ofPage 2 of 7
(page number not for citation purposes)
BMC Cancer 2009, 9:342 http://www.biomedcentral.com/1471-2407/9/342Cancer Hospital, Fudan University, Shanghai, China. All
primary monoclonal antibodies for estrogen receptor
(ER), progesterone receptor (PR) and ERBB2 were from
Dako. The staining results were assessed by at least two
pathologists, using a semiquantitative scoring system,
where integrated the proportion score and the intensity
score. The proportion score, indicating the percentage of
tumor cells stained, was interpreted such that a score of 0
required no staining seen, 1 required ≤25% of cells posi-
tive, 2 required 25-50% of cells stained, 3 required 50-
75% of positive cells and 4 required >75% of staining
cells. As to the intensity score, a negative result was
defined as a score of 0, weakly positive as 1, moderately
positive as 2, and strongly positive as 3. The final score
was calculated as the product of the proportion score and
the intensity score. Thereby, staining results ranged from
score 0 to 12. The scoring system for ER and PR was
defined as negative for score 0 and positive for scores of
1~12 with the nucleic staining of carcinoma cells, whereas
ERBB2 was defined as negative for scores of 0~8 (namely,
0, 1+ and 2+ in the DAKO scoring system) and positive for
strong membranous staining with scores of 9~12 (namely
DAKO score 3+).
Statistical analysis
Clinicopathological parameters were compared between
different subgroups using one-way analysis of variance
(ANOVA) test for continuous variables, chi-square test for
unordered categorical variables and nonparametric
Kruskal-Wallis rank test for ordinal categorical variables.
Site-specific relapse-free survival (RFS) was defined as the
time from surgery to the earliest occurrence of an event,
including locoregional, visceral and bone relapse. Locore-
gional failure was defined as a first relapse on the chest
wall or in the ipsilateral breast, the ipsilateral axilla, the
ipsilateral supraclavicular or infraclavicular fossa, or the
ipsilateral internal mammary region [19], which was
required to be identified by biopsy or fine needle aspira-
tion. Visceral metastasis was established if there was any
radiological evidence of metastases to viscera (including
lung, liver and brain). Bone relapse was defined as metas-
tases to bone without visceral metastasis. Any suspicious
lesions on bone scan should be confirmed by further X-
ray or CT/MRI examination. Those without any evidence
of event were censored at the last date they were known to
be alive.
Survival analyses were estimated by the Kaplan-Meier
method and were compared using the log-rank test. Mul-
tivariate Cox proportional hazards regression analyses
were applied to modeling the relationship between sub-
group and RFS, adjusted for age (≤50 vs. >50), tumor size
(≤2 cm vs. >2 cm), number of axillary lymph nodes
(ALNs) involved (0, 1-3, ≥4), histological grade (I/II vs.
III) and systemic treatment (yes vs. no). Hazard ratios
(HRs) were presented with their 95% confidence intervals
(CIs). For graphical display of RFS, annual hazard rates
were estimated using a Kernel method of smoothing. All
statistical tests were two sided and P < 0.05 was consid-
ered to be statistically significant. All statistical analyses
were performed with Stata statistical software package




The mean age at diagnosis was 52.7 years old (range 24-
90). Median follow-up was 3.15 years, ranging from 2
months to 7.8 years. According to different combinations
of HR and ERBB2 status, 1662 patients were classified into
the three subgroups as follows: triple negative (19.31%),
ERBB2+ (26.72%) and HR+/ERBB2- (53.97%, HR+
referred to ER+ or PR+). When compared with triple neg-
ative and ERBB2+ tumors, less relapse events were
observed in HR+/ERBB2- patients (15.89% and 14.64%
vs. 8.81%, P < 0.001; Table 1).
Locoregional RFS and relapse hazard
We found a statistically significant difference in locore-
gional RFS between the three subgroups (log-rank P =
0.007, Fig. 1; adjusted P < 0.05, data not shown). Com-
pared with the triple negative patients, locoregional RFS
was significantly better for HR+/ERBB2- counterparts (P =
0.027; HR = 0.521, 95% CI 0.293-0.927; Table 2), but
nearly comparable to ERBB2+ tumors (P = 0.221; HR =
0.686, 95% CI 0.375-1.254; Table 2). Besides, the survival
curves of locoregional failure for triple negative and
ERBB2+ patients were virtually superimposable. Some-
what differently in the hazard curves, the former showed
an early major surge reaching the maximum at approxi-
mately 2 years after surgery, while the corresponding peak
for the latter was at 1.5 years (Fig. 2).
Visceral RFS and relapse hazard
A statistically significant difference was yielded in visceral
RFS among the three subgroups (log-rank P = 0.025, Fig.
3; adjusted P < 0.05, data not shown). The multivariate
Cox regression analysis demonstrated that triple negative
patients, similar to ERBB2+ counterparts (P = 0.889; HR =
0.952, 95% CI 0.479-1.893; Table 2), tended to have
more visceral relapses than HR+/ERBB2- women (P =
0.005; HR = 0.339, 95% CI 0.158-0.724; Table 2) across
all time periods. Furthermore, the early relapse peak
appeared to occur later in triple negative phenotype than
that in ERBB2+ subgroup, as opposed to a relatively flat
hazard rate until 4 years for HR+/ERBB2- category (Fig. 4).
Bone RFS and relapse hazard
There was no difference in RFS among the three groups in
the univariate survival analysis (log-rank P = 0.180; Fig 5).
Nevertheless, when compared to triple negative patients,Page 3 of 7
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discerned in the multivariate Cox regression analysis for
ERBB2+ women (P = 0.048; HR = 0.384, 95% CI 0.148-
0.991), with the borderline significance for HR+/ERBB2-
breast cancers (P = 0.058; HR = 0.479, 95% CI 0.224-
1.025; Table 2). This finding was confirmed by the further
analysis of hazard function (Fig. 6).
Discussion
This study is, to the best of our knowledge, the first as well
as the largest retrospective analysis on site-specific relapse
pattern for triple negative tumors in Chinese breast cancer
patients. As to locoregional failure, we demonstrated that
RFS for the triple negative category was inferior to that for
HR+/ERBB2- patients, but comparable to that for ERBB2+
Table 1: Summary of subgroup characteristics in 1662 patients
Variables (%) Triple negative ERBB2+ HR+/ERBB2- P value
n = 321 n = 444 n = 897
Mean age at diagnosis (year,  ± SD) 52.02 ± 10.49 52.12 ± 9.99 53.16 ± 11.56 0.416
Tumor size
≤ 2 cm 139 (43.30) 148 (33.33) 439 (48.94) < 0.001
>2 cm 182 (56.70) 296 (66.67) 458 (51.06)
Number of ALNs involved
0 190 (59.19) 233 (52.48) 538 (59.98)
1-3 72 (22.43) 107 (24.10) 214 (23.86) 0.020
≥ 4 59 (18.38) 104 (23.42) 145 (16.16)
Histological grade
I/II 151(61.56) 237 (74.29) 499 (81.80) 0.002
III 60 (28.44) 82 (25.71) 111 (18.20)
Not known 110 126 287
Systemic treatment
Yes 302 (94.08) 426 (95.95) 852 (94.98) 0.494
No 19 (5.92) 18 (4.05) 45 (5.02)
All relapse
Yes 51 (15.79) 65 (14.64) 79 (8.81) < 0.001
No 270 (84.11) 379 (85.36) 818 (91.19)
Locoregional relapse
Yes 25 (7.79) 35 (7.79) 35 (3.90) 0.003
No 296 (92.21) 409 (92.12) 862 (96.10)
Mean TTE (years) 2.19 2.03 2.02 ------
Visceral relapse
Yes 15 (4.67) 25 (5.63) 23 (2.56) 0.014
No 306 (95.33) 419 (94.37) 874 (97.44)
Mean TTE (years) 1.64 2.02 2.49 ------
Bone relapse
Yes 12 (3.74) 7 (1.58) 16 (1.78) 0.074
No 309 (96.26) 437 (98.42) 881 (98.22)
Mean TTE (years) 3.04 2.24 2.57 ------
Abbreviations: HR = hormone receptor; SD = standard deviation; ALNs = axillary lymph nodes; TTE = time to event
x
Table 2: Cox proportional hazards regression analysis of RFS for locoregional, bone and visceral relapse in 1662 breast cancer patients
Subgroup* Univariate Cox model, HRs (95% CI) P value Multivariate Cox model, HRs (95% CI) P value
Locoregional RFS
ERBB2+ 1.018(0.609-1.700) 0.947 0.686(0.375-1.254) 0.221
HR+/ERBB2- 0.522(0.312-0.873) 0.013 0.521(0.293-0.927) 0.027
Visceral RFS
ERBB2+ 1.203(0.634-2.281) 0.572 0.952(0.479-1.893) 0.889
HR+/ERBB2- 0.568(0.296-1.090) 0.089 0.339(0.158-0.724) 0.005
Bone RFS
ERBB2+ 0.468(0.183-1.198) 0.113 0.384(0.148-0.991) 0.048
HR+/ERBB2- 0.553(0.259-1.178) 0.124 0.479(0.224-1.025) 0.058
*Triple negative category was used as the reference group.
Abbreviations: RFS = relapse-free survival; HRs = hazard ratios; CI = confidence interval; HR = hormone receptorPage 4 of 7
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with conflicting results. According to Rodriguez-Pinilla's
reports, a higher percentage of local recurrence arose in tri-
ple negative tumors [13], which was somewhat congruent
with our analysis. In contrast, other researchers found no
significant association of triple negative phenotype with
shorter local relapse-free survival (LRFS) [15,20]. Addi-
tionally, Haffty's observation revealed that the triple neg-
ative cohort had a predilection for relapse in regional
nodes with marginal significance (P = 0.05) [15], which
partly supported our findings.
Although Dent and colleagues observed a prominent
increase in the rate of visceral metastasis for triple negative
patients when compared with that for non-triple negative
patients [21], it still remains unclear whether triple nega-
tive patients have a greater risk of visceral metastasis than
ERBB2+ patients. We found that the risk of developing a
visceral metastasis as the site of the first recurrence was sig-
nificantly higher in women with triple negative and
ERBB2+ breast cancers than in women with HR+/ERBB2-
tumors. Besides, we also documented that the peak in the
hazard rate for visceral metastasis was later for triple neg-
ative patients than ERBB2+ patients. These findings sug-
gest that the pattern of visceral metastasis for the triple
negative cases may be intermediate between that for HR+/
ERBB2- and ERBB2+ groups in Chinese breast cancer
patients.
Locoregional relapse-free survival for different subgroups in 1662 breast cancer pati ntsFigu  1
Locoregional relapse-free survival for different sub-
groups in 1662 breast cancer patients.
Annual locoregional relapse hazard rates for different sub-groups in 1662 breast c nc r patientsFig re 2
Annual locoregional relapse hazard rates for differ-
ent subgroups in 1662 breast cancer patients.
Visceral relapse-free survival for different subgroups in 1662 breast cancer pati ntF gu e 3
Visceral relapse-free survival for different subgroups 
in 1662 breast cancer patients.
Annual visceral relapse hazard rate for different subgroups in 1662 breast c ncer patientsFigure 4
Annual visceral relapse hazard rate for different sub-
groups in 1662 breast cancer patients.Page 5 of 7
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established to predict the risk of bone metastasis in breast
cancer [22,23]. With the considerable understanding of
intrinsic molecular subtypes, it is far from satisfactory to
determine the clinical outcome exclusively by HR status.
It has been reported that there was no difference in the
rate of bone metastasis between triple negative and non
triple negative groups [13,21]. Unfortunately, the previ-
ous studies overlooked the respective contribution of HR
and ERBB2 status to the development of bone spread. In
the present analysis, the triple negative phenotype
brought about a dramatic increase in the hazard of devel-
oping bone metastasis with statistical significance com-
pared with ERBB2+ subtype (P < 0.05). Furthermore, a
similar trend was also observed between triple negative
and HR+/ERBB2- groups with borderline significance (P =
0.058). In this sense, those with ERBB2+ tumors metasta-
sized less often to bone than ERBB2- breast cancers, which
was relatively consistent with Kallioniemi's findings [24].
Taken together, all of these data inferred that the ERBB2
status, besides HR status, should be taken into account
when talking about the risk of bone metastasis, as exem-
plified by triple negativity.
This study has some potential and inevitable limitations
due to its retrospective nature. Recurrences might be
somewhat underreported or misinformed for a substan-
tial portion of the patients in this database; nonetheless,
underreporting or misinformation of recurrences would
have not varied by clinicopathological parameters [25].
We did not evaluate the effect of treatment on survival in
the present study, but all the hazard ratios were adjusted
for treatment administered [11]. Furthermore, the limited
sample size and the lack of more detailed molecular pro-
filing are also potential weaknesses.
Conclusion
In conclusion, our data show that preferential relapse sites
for triple negative breast cancers may be quite distinct
from that for HR+/ERBB2- and ERBB2+ counterparts in
Chinese breast cancer patients. It indicates that different
organotropism may be due to the different intrinsic sub-
types. Therefore, a better knowledge of organotropism in
different intrinsic subtypes is warranted for efficacious
systemic treatment to decrease and/or delay the recur-
rence hazard.
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